This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-16. Anything still debated is marked as such rather than presented as settled.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Foremost is the incorporation of radionuclides into the metal-organic framework as the metal nodes. This effectively captures the actinides by incorporating them into the rigid crystal structure itself, locking it in place. The incoperation of actinides as metal nodes can be achieved through a variety of methods, including synthesis, metal-node extension, and cation exchange. Actinide-containing metal-organic frameworks can be synthesized directly from actinide salts, allowing for direct incorporation without further or previous modification required. Additionally, the metal-node can be extended, allowing for a combination of actinides and transition metals to serve as the nodes simultaneously. Finally, actinides can be incorporated into the metal node through cation exchange; a previously-synthesized metal-organic framework is exposed to actinide cations, where the radionuclides are allowed to slowly replace the transition metal as the metal nodes, incorporating themselves into the crystal itself. Another known method by which metal-organic frameworks capture radionuclides is through the binding/anchoring of these cations to functionalized organic linkers. These organic linkers commonly utilize nucleophilic moieties known to bind and anchor to cations; such moieties include carboxylic acid groups and crown ethers. This binding/anchoring drastically slows the rate of actinides leaching from the framework. For example, carboxylic acid-functionalized linkers have been used to drastically slow the leaching of 241Am into dimethylformamide from a zirconium-based framework.
== Resurgence of Freemasonry in Cuba == In 1855, mainland Spain saw the triumph of the Spanish Revolution of 1854 and the Progressive Biennium. The Cuban oligarchy at the time was highly connected with the reformists of the Liberal Union, especially the former Governor of Cuba, Leopoldo O'Donnell had led the revolution. Reformist ideas were implemented in Cuba in 1857; the freedom of speech, freedom of the press, and the freedom of assembly. With that newfound political freedom, Freemasonry was allowed to reform in Cuba.
=== 2011–2022 === KBL-BML-Unilabo Laboratory ("KBL"), based in Antwerp and the Woestyn Laboratory, based in Mouscron, January 2011 Physicians' Automated Laboratory ("PAL"), based in Bakersfield, California, US, January 2011 The laboratory business of Central Coast Pathology Consultants ("CCPC"), a high quality laboratory in California, US, February 2011 In June 2015, Sonic acquired Medisupport, based in Switzerland. In the same month, Sonic acquired KLD Laboratory, based in Belgium. In 2011, Sonic acquired the Woestyn Laboratory (Belgium), cytopathology business Labor Dr. Steinberg (Germany), Central Coast Pathology (San Luis Obispo, California), and Allied Medical and Australian Skin Cancer medical centre groups. In 2012, the company acquired Labor Oldenburg Dr. Müller (Germany) and the Western Australian pathology operations of Healthscope. In 2013, IPN acquired the Australian Locum Medical Service group and Sonic acquired Labco S.A. Group (Germany). In 2014, Sonic acquired San Pathology (Sydney). In 2015, Sonic acquired Medisupport S.A (Switzerland) and Klinisch Laboratorium Declerck (Ardooie, Belgium). In Australia, the company acquired Adelaide Pathology Partners and the Medibank Workplace Health (WPH) and Travel Doctor businesses. In 2016–2017, Sonic acquired 80% ownership of GLP systems (Hamburg, Germany). It acquired Staber Laboratory group (Munich, Germany), Medical Laboratory Bremen, and West Pacific Medical Laboratory (Los Angeles, California).
Sources: en.wikipedia.org
In 1966 the Johns Hopkins Gender Identity Clinic opened; it was one of the first in the US to provide care for transgender individuals, including hormone replacement therapy, surgery, psychological counseling, and other gender affirmative healthcare. The clinic required patients before a gender affirmation surgery to go through a program called "Real Life Test". The Real Life Test was a program where before a gender affirming surgery the patient was required to live with their desired gender role. In 1979 the clinic was closed by the newly appointed director of psychiatry Paul R. McHugh.
School of Medicine is one of the two departments of the School of Health Sciences, University of Patras. The School of Medicine of the University of Patras was founded in 1977 and admitted its first students in October of the same academic year. During the functioning of 28 years, received a degree 2321 students Medicine and dozens another with MSc and PhD.
On April 18, days after findings from the medical examiner's review were published, two more deaths occurred, though once again their connection to cheese heroin took weeks to be confirmed. The body of 18-year-old Keridma Godina was found on a porch in Balch Springs the day after her death; police charged two men immediately with abandoning the body, but were unable to make any drug-related charge when confirmation of the link to cheese came three weeks later. The death of 17-year-old Lauren Paulson of The Colony, was reported that same week, but was not linked to cheese heroin until late summer. In mid-May, the Dallas County medical examiner's office confirmed that two earlier teen deaths — one in January and another in April — were confirmed by toxicology tests as linked to cheese heroin; these additions brought the known toll at that time to 21 deaths among those 18 and under, not including the Paulson case. Over the summer vacation months of 2007, the push against cheese heroin continued. Parents and police organized a June 30 March, Sen. John Cornyn visited the area as part of an anti-cheese campaign in early July, the director of the White House Office of National Drug Control Policy gave a press conference from Dallas ISD headquarters in August praising the district's efforts, and local stores pulled Tylenol PM and similar drugs from the shelves to make them less accessible.
=== Pharmacodynamics === MDDMA shows reduced potency as a monoamine releasing agent and reuptake inhibitor compared to MDA and MDMA. It was 11-fold less potent than MDMA and 4-fold less potent than MDA as a serotonin releasing agent (SRA). Moreover, whereas MDA and MDMA are serotonin–norepinephrine–dopamine releasing agents (SNDRAs), MDDMA is a selective SRA along with ≥10-fold weaker dopamine and norepinephrine reuptake inhibition. The related drug MDTMA is completely inactive as a monoamine releasing agent, though it does still show very weak monoamine reuptake inhibition. Another related drug, dimethylamphetamine, is said to be a prodrug of methamphetamine and amphetamine, although it is much less potent and weaker than these drugs. (R)-MDDMA has been found be inactive as a serotonin releasing agent but to act as a partial agonist of the serotonin 5-HT2A and 5-HT2C receptors. Conversely, unlike MDMA, it was inactive as a serotonin 5-HT2B receptor agonist. In animal studies, (R)-MDDMA did not produce the head-twitch response, affect body temperature, or induce hyperlocomotion, and showed diminished or no prosocial effects. On the other hand, it produced psychoplastogenic effects mediated by serotonin 5-HT2 receptor activation as well as promoted fear extinction and induced antidepressant-like effects. It was concluded that (R)-MDDMA is a non-hallucinogenic psychoplastogen with improved safety compared to MDMA and (R)-MDMA.
Sources: en.wikipedia.org
== Characterization of inorganic compounds == Because of the diverse range of elements and the correspondingly diverse properties of the resulting derivatives, inorganic chemistry is closely associated with many methods of analysis. Older methods tended to examine bulk properties such as the electrical conductivity of solutions, melting points, solubility, and acidity. With the advent of quantum theory and the corresponding expansion of electronic apparatus, new tools have been introduced to probe the electronic properties of inorganic molecules and solids. Often these measurements provide insights relevant to theoretical models. Commonly encountered techniques are:
The UK quits the Energy Charter Treaty, which had allowed fossil fuel companies to sue governments over profits lost in the drive towards net zero. Data from the Office for National Statistics shows a surplus in government finances of £16.7bn in January 2024, more than double the figure for January 2023. 22 February More than 60 MPs have signed a House of Commons motion calling for the resignation of Speaker Sir Lindsay Hoyle. A further 50 sanctions against Russia are announced, aimed at restricting those supplying its military with munitions such as rocket launchers, missiles and explosives. Employees of a company contracted by the Home Office are suspended after a baby's birth certificate was returned to the parents with the place of birth, Israel, crossed out. The UK government announces that legislation will be introduced to clear hundreds of sub-postmasters in England and Wales who were wrongly convicted as a result of the Horizon IT scandal. 23 February Thousands of people in the Keyham area of Plymouth, Devon are evacuated as an unexploded World War II bomb is moved by military convoy for disposal at sea. The bomb was discovered in a garden three days prior. This is also the first time that the UK Emergency Alert System is used in a live situation. Ofgem confirms that the average annual energy bill will fall by £238 from April to £1,690, its lowest rate for two years. Shamima Begum loses her legal bid to overturn the decision to revoke her UK citizenship. Ibrahima Bah is sentenced to nine years and six months in prison.
=== Lungs === Individuals with Marfan syndrome may be affected by various lung-related problems. Spontaneous pneumothorax can be present, but is not common. In spontaneous unilateral pneumothorax, air escapes from a lung and occupies the pleural space between the chest wall and a lung. The lung becomes partially compressed or collapsed. This can cause pain, shortness of breath, cyanosis, and if not treated, death. Other possible pulmonary manifestations of MFS include sleep apnea, which is typically treated with BiPAP. and idiopathic obstructive lung disease. Pathologic changes in the lungs have been described such as cystic changes, emphysema, pneumonia, bronchiectasis, bullae, apical fibrosis and congenital malformations such as middle lobe hypoplasia.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.